Roy­al­ty Phar­ma pays Fer­ring $300M for 5% roy­al­ty on sales of can­cer gene ther­a­py Ad­sti­ladrin

Fer­ring Phar­ma­ceu­ti­cals is pulling in $300 mil­lion and a po­ten­tial $200 mil­lion mile­stone from Roy­al­ty Phar­ma in ex­change for a 5.1% per­cent­age roy­al­ty on net sales of its gene ther­a­py Ad­sti­ladrin, just as it gears up to roll out the treat­ment com­mer­cial­ly.

The $200 mil­lion mile­stone pay­ment de­pends on hit­ting man­u­fac­tur­ing goals in 2025, while the roy­al­ty pay­ments are ex­pect­ed to end in the ear­ly- to mid-2030s. Ac­cord­ing to Fer­ring, the mon­ey from Roy­al­ty Phar­ma will be used to scale up man­u­fac­tur­ing, com­mer­cial­iza­tion and clin­i­cal de­vel­op­ment for the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER